异普拉酮 | 56463-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 异普拉酮
• 英文名称: 3-amino-4-isobutyryl-5-methyl-2-phenylpyrrole
• 英文别名: Isoprazone；1-(4-amino-2-methyl-5-phenyl-1H-pyrrol-3-yl)-2-methylpropan-1-one
• CAS: 56463-68-4
• 化学式: C₁₅H₁₈N₂O
• 分子量: 242.321
• InChiKey: UMSWVMUFXHQAPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  425.9±45.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丁酰基丙酮 在 sodium methylate 、 对甲苯磺酸 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 10.0h， 生成 异普拉酮
  参考文献：
  名称：

  Tarzia; Panzone; Leali, Farmaco, Edizione Scientifica, 1984, vol. 39, # 6, p. 538 - 558

  摘要：

  DOI：

文献信息

• Aminopyrrole derivatives
  申请人：Gruppo Lepetit S.p.A.

  公开号：US04140696A1

  公开（公告）日：1979-02-20

  Pharmacologically-active aminopyrrole derivatives of the formula ##STR1## wherein: R is selected from hydrogen, (C.sub.1-4)alkyl, benzyl and chlorobenzyl; R.sub.1 is selected from hydrogen, (C.sub.1-4)alkyl, phenyl and phenyl substituted by a radical selected from methyl, ethyl, methoxy, ethoxy, benzyloxy, fluoro, chloro and bromo; R.sub.2 and R.sub.3 individually represent hydrogen or (C.sub.1-4)alkyl or, taken together, represent an isopropylidene, a benzylidene or a chlorobenzylidene radical; R.sub.4 is selected from (C.sub.2-4)alkanoyl; carbo(C.sub.1-3)alkoxy; benzoyl, benzoyl substituted by a radical selected from chloro, methoxy or ethoxy; carbamoyl, methylcarbamoyl and phenyl carbamoyl; R.sub.5 is selected from hydrogen, (C.sub.1-4)alkyl, carbo(C.sub.1-3)alkoxy, carbomethoxymethyl, carbethoxymethyl, trifluoromethyl and carbamoyl, with the proviso that when R is hydrogen, R.sub.1 and R.sub.5 are methyl and R.sub.4 is carbethoxy, R.sub.2 and R.sub.3 cannot simultaneously represent hydrogen; And a salt thereof with a pharmaceutically acceptable acid. The compounds have anti-inflammatory and CNS-depressant utility. They are also useful as analgesics and antipyretics and display a very low degree of anti-ulcerogenic activity.

  药理活性的氨基吡咯衍生物的化学式为##STR1##其中：R从氢、(C.sub.1-4)烷基、苄基和氯苄基中选择；R.sub.1从氢、(C.sub.1-4)烷基、苯基和苯基取代基中选择，所述取代基为甲基、乙基、甲氧基、乙氧基、苄氧基、氟、氯或溴；R.sub.2和R.sub.3分别代表氢或(C.sub.1-4)烷基，或者合并表示异丙亚甲基、苄亚甲基或氯苄亚甲基基团；R.sub.4从(C.sub.2-4)烷酰基；羧基(C.sub.1-3)烷氧基；苯甲酰基，苯甲酰基取代基为氯、甲氧基或乙氧基；氨基甲酰基，甲基氨基甲酰基和苯基氨基甲酰基中选择；R.sub.5从氢、(C.sub.1-4)烷基、羧基(C.sub.1-3)烷氧基、羧甲氧基甲基、羧乙氧基甲基、三氟甲基和氨基中选择，但当R为氢时，R.sub.1和R.sub.5为甲基，R.sub.4为羧乙氧基，R.sub.2和R.sub.3不能同时表示氢；以及其与药学上可接受的酸形成的盐。这些化合物具有抗炎和中枢神经系统抑制作用。它们还可用作镇痛剂和退烧剂，并显示出非常低的抗溃疡活性。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• US4140696A
  申请人：——

  公开号：US4140696A

  公开（公告）日：1979-02-20